Treatment for Acne Vulgaris

Acne is the most common skin disease in the US and affects 80% of the population at some point in life.

» Study Details | Apply for the Study

Upcoming Studies for Men & Women

» Study Details | Apply for the Study

Irritable Bowel Syndrome Experiencing Abdominal Pain

The CAPTIVATE Study is a clinical study to evaluate how an investigational study medication called olorinab may reduce abdominal pain in people with IBS. You are being asked to see if you qualify in this study. The investigational study medication has been previously tested in healthy volunteers and in a small group of people with Crohn’s disease experiencing abdominal pain. The investigational study treatment in the CAPTIVATE Study is taken orally 3 times a day. This study is designed to evaluate whether olorinab can reduce abdominal pain associated with IBS.

You may be eligible to participate in this study if you: are

18-70 years of age have been diagnosed with IBS with constipation or diarrhea (IBS-C or IBS-D) experience abdominal pain due to IBS  

Other eligibility criteria apply.

Eligible participants will receive study-related health assessments and study-related treatment (olorinab or placebo) at no cost. You'll be paid for each completed visit. Enrollment is currently open for this study.

» Study Details | Apply for the Study

Celiac Disease on a Gluten Free Diet

If you are experiencing celiac disease symptoms despite following a gluten-free diet, you may want to talk to your doctor about our clinical study.

» Study Details | Apply for the Study

Ulcerative Colitis Study

A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis

» Study Details | Apply for the Study

Moderately to Severely Active Crohn’s Disease

A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Crohn’s Disease

» Study Details | Apply for the Study

Moderate to Severe Endometriosis-Associated Pain

Endometriosis is a chronic oestrogen-dependent condition characterised by the growth of endometrial tissue in sites other than the uterine cavity, most commonly the pelvic cavity (including the ovaries), the uterosacral ligaments, the pouch of Douglas, the rectosigmoid colon, and the bladder and distal ureter

» Study Details | Apply for the Study

heavy menstrual bleeding associated with uterine fibroids in premenopausal

Heavy Menstrual Bleeding Associated with Uterine Fibroids

» Study Details | Apply for the Study

Hot Flashes Associated with Menopause

Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause

» Study Details | Apply for the Study

Women with Endometriosis Experiencing Endometrial Related Pain

The INANNA study is evaluating an investigational medication in women with moderate or severe endometriosis pain. You may qualify to participate if you: •• Are between 18 and 49 years of age •• Have been diagnosed with endometriosis within the last 5 years •• Have a 21-38 day menstrual cycle •• Are not pregnant, nursing or planning a pregnancy within the next 12 months •• Are willing to stop taking current hormonal endometriosis therapies (use of nonhormonal contraception methods is required during the study) Other criteria will be reviewed to determine if you qualify for this study.

» Study Details | Apply for the Study

Moderate to Severe Atopic Dermatitis in Adolescent

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent Subjects with Moderate to Severe Atopic Dermatitis

» Study Details | Apply for the Study

RAPID COVID-19 Symptoms Testing

 “Clinical Evaluation of the Panbio™ COVID-19 Ag AnTigen (Ag) Assay in Symptomatic Subjects (CATSS)”

» Study Details | Apply for the Study